SUMMARY The potencies of six commerically manufactured heparins have been measured by the British Pharmacopoeial (BP) assay and activated partial thromboplastin time (APTT), protamine sulphate, and anti-Xa assays. The APTT/BP potency ratios were found to vary with the preparation but this was not dependent on the tissue source of heparin. For mucosal heparins, the anti-Xa/BP potency ratios were close to unity, but for heparin of lung origin the anti-Xa potency was approximately one-quarter of the BP potency. Four heparin fractions prepared by column gel chromatography of a commerical heparin were similarly examined by all four assays, and there was a wide divergence between the BP potency estimates and those obtained with the other methods. The degree of divergence was found to depend on the molecular size of the fraction.
Heparin is used widely in low-dose regimes for prophylaxis and in therapeutic doses for the treatment of established venous thromboembolism. In its antithrombotic role, heparin is used to potentiate an anti-Xa action of antithrombin III. The mode of action of heparin as an anticoagulant is less clear, and, when used in this way, the risk of haemorrhage is monitored by clotting assays such as the activated partial thromboplastin time (APTT). As generally marketed, heparin is standardised with a pharmacopoeial technique such as the British Pharmacopoeial (BP) assay. Since the activity of commerically manufactured heparin varies with the tissue source of heparin, with the molecular weight composition, and the assay method, the use of one pharmacopoeial method to characterise the varying roles of heparin (antithrombotic and anticoagulant) is open to question. In this investigation several heparins manufactured commercially (from lung and mucosa) have been assayed by a variety of techniques to provide information on the adequacy of the BP assay to measure the activity of unfractionated heparins. In addition, heparin fractions separated from one commerical preparation have been similarly examined.
HEPARIN ASSAYS
The British Pharmacopoeial assay' was modified according to Walton 50 pl of the fraction with 3 ml of an aqueous solution of 0-0025% w/v toluidine blue and measuring the transmittance at 500 nm relative to that for known concentrations of the reference heparin preparation. Fractions corresponding to major areas of the elution curve were collected into four pools ( Figure) and the specific activity of each pool was determined by the four assays.
Results
The specific activities of all heparin preparations measured by each of the four techniques as well as the coefficient of variation are shown in Table 1 a. The coefficient of variation derived from 15 measurements on the Allen and Hanburys heparin preparation is largest for the anti-Xa method and least for the BP assay using the coagulometer. It can be seen that the specific activity varies with the pre- In Table lb the potencies of all heparins measured by the BP assay are given as a percentage of the labelled potency (units/ml). The potencies obtained by the other assays are expressed relative to the BP potency. The APTT/BP ratios varied from 1 06 for heparin by Commonwealth Serum Laboratories to 1 40 for Upjohn heparin. This variation appeared to be unrelated to the tissue source of the preparation. For the mucosal heparins the anti-Xa/BP ratios were close to unity, while for the Upjohn lung heparin the anti-Xa potency was a quarter of the BP potency. The potencies determined by the protamine titration assay were generally in agreement with the BP potencies, although the protamine titration/BP ratio was significantly greater than unity for Boots heparin. The anti-Xa/APTT ratio varied from 0-66 to 093 for the mucosal preparations while it Anti-Xa/APTT ratio 0 56 0-72 0-80 2-08
The results are expressed as a ratio of the value obtained by the BP assay. Anti-Xa/APTr ratios for the four pools are also shown. These ratios are derived from the specific activities shown in the Figure. was only 019 for the lung heparin. The specific activities of the four pools obtained by fractionating Allen and Hanburys heparin were determined by the four assays and these are shown in the Figure. It can be seen that the specific activities measured for the four pools depend upon the assay method and on the molecular size of the fraction. Table 2 shows the measured potencies for these four pools relative to the BP potency as well as the anti-Xa/APTT ratio. For pool 1 the heparin potency obtained by the BP method is more than twice those obtained by the other methods. For pools 2 and 3, the potency ratios (relative to the BP method) show a marked increase as the molecular size decreases. The anti-Xa/BP ratio showed a further increase in pool 4 while the APTT/BP ratio showed a dramatic decrease. This is reflected in the anti-Xa/APTT ratio which was 2-08 for pool 4 (the smallest molecular size pool) but less than 1 for the other pools.
Discussion
Commercially marketed heparins are assayed against a pharmacopoeial assay. In the investigations described, we have examined six commercial heparins with a variety of assays. Although significant variations were found in the six heparins tested using the BP method, all the measured potencies (including that of the Upjohn heparin, which complies with the requirements of the United States Pharmacopoeia) were within the tolerance limits specified in the British Pharmacopoeia.'
Investigations described in this study show that the assigned potency of commercial heparins can vary according to the assay used and that those obtained with the BP assay are not necessarily representative of the values obtained with other methods. The APTT/BP potency ratios varied considerably with the preparation but this was found not to depend on the tissue source of heparin. In four of the six heparins tested, the APTT method gave a higher measurement of heparin than did the BP assay. On the other hand, when the BP assay was compared with the anti-Xa method, good agreement was obtained for the heparins of mucosal origin. For the lung heparin, the potency measured with the anti-Xa assay was found to be markedly reduced. This is reflected in the difference between the anti-Xa/ APTT potency ratios for lung and mucosal heparins. It has been shown previously6 that this ratio was less than 1-0 for lung and greater than 1.0 for mucosal heparin.
Differences between the estimates obtained by the BP method and the other assays were even more pronounced when the various assays were tested against fractions of heparin. Higher potency values of the large molecular size fractions were found using the BP method than with the other methods. Conversely, the small molecular size fractions gave higher assay values with the other methods. The discrepancies between the potency estimates using the BP method and the other clinical methods observed in this investigation may be due in part to the use of animal blood7 in the BP assay. The anti-Xa/ APTT ratio varied with the molecular size of heparin fraction and was dramatically raised in the fraction with the lowest molecular size.
A number of studies have shown that, after parenteral administration, heparin-induced prolongation in the APTT is similar regardless of the tissue source.f-11 In contradistinction, the difference between the lung and mucosal heparins in potentiating anti-Xa activity in vitro is also clearly demonstrable in vivo after injection into human subjects. 6 Since the APTT potencies of the lung and mucosal heparins are similar, both in vitro and in vivo, the large difference in the anti-Xa/APTT ratio between the two sources of heparins originates predominantly in their anti-Xa potencies. This finding may be of some relevance to the current clinical practice of heparin administration in low dosage for its antithrombotic action. It has been assumed6 that, for optimal antithrombotic prophylaxis, heparin with a high anti-Xa/APTT ratio is more desirable than one with a lower ratio since such a preparation might confer enhanced protection for an equivalent risk of haemorrhage. However, it has been shown in the dog'2 that mucosal heparin causes significantly greater 'delayed haemorrhage' than lung heparin and that protamine reversal is significant only with lung heparin. It seems that only the APTT potency of the two heparins is capable of being reversed completely, and a significant fraction of the initial anti-Xa potency remains unneutralised."3 It is possible that the unneutralised anti-Xa activity underlies the failure of protamine to reduce effectively the incidence of 'delayed haemorrhage' with heparin of mucosal origin. Thus, the possibility remains that the use of a heparin preparation with a high anti-Xa/APTT ratio may also be associated with an enhanced risk of haemorrhage.
